Cargando…

Hyper-activated PI3K-δ in immunodeficiency

Detalles Bibliográficos
Autores principales:	Heurtier, Lucie, Deau, Marie-Céline, Kracker, Sven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621884/ https://www.ncbi.nlm.nih.gov/pubmed/26286043

Ejemplares similares

Two Monogenetic Disorders, Activated PI3-Kinase-δ Syndrome 2 and Smith–Magenis Syndrome, in One Patient: Case Report and a Literature Review of Neurodevelopmental Impact in Primary Immunodeficiencies Associated With Disturbed PI3K Signaling
por: Moreno-Corona, Nidia, et al.
Publicado: (2021)

Epstein–Barr Virus Susceptibility in Activated PI3Kδ Syndrome (APDS) Immunodeficiency
por: Carpier, Jean-Marie, et al.
Publicado: (2018)

Activated PI3Kinase Delta Syndrome—A Multifaceted Disease
por: Thouenon, Romane, et al.
Publicado: (2021)

Activated PI3Kδ syndrome – reviewing challenges in diagnosis and treatment
por: Vanselow, Sven, et al.
Publicado: (2023)

PI3Kδ hyper-activation promotes development of B cells that exacerbate Streptococcus pneumoniae infection in an antibody-independent manner
por: Stark, Anne-Katrien, et al.
Publicado: (2018)

The Treatment of Activated PI3Kδ Syndrome
por: Coulter, Tanya I., et al.
Publicado: (2018)

Immunodeficiency-Associated Lymphoid Hyperplasia As a Cause of Intussusception in a Case of Activated PI3K-δ Syndrome
por: Mettman, Daniel, et al.
Publicado: (2017)

Activated PI3Kδ syndrome, an immunodeficiency disorder, leads to sensorimotor deficits recapitulated in a murine model
por: Serra, Ines, et al.
Publicado: (2021)

A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome
por: Rao, V. Koneti, et al.
Publicado: (2023)

Regulation of T cell alloimmunity by PI3Kγ and PI3Kδ
por: Uehara, Mayuko, et al.
Publicado: (2017)

Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib
por: Till, Kathleen J., et al.
Publicado: (2023)

PI3Kδ is indispensable for CTL-mediated cytotoxicity
por: Putz, Eva M, et al.
Publicado: (2011)

Epidermodysplasia verruciformis in a young adult with activated PI3Kδ syndrome
por: Donaldson, Stephanie L., et al.
Publicado: (2019)

Allosteric activation of PI3Kα by oncogenic mutations
por: Burke, John E., et al.
Publicado: (2013)

The role of PI3Kγ in metabolism and macrophage activation
por: Solinas, Giovanni, et al.
Publicado: (2017)

A Review of Phosphocreatine 3 Kinase δ Subtype (PI3Kδ) and Its Inhibitors in Malignancy
por: Xiang, Qiong, et al.
Publicado: (2021)

Discovery of Novel PI3Kδ Inhibitors Based on the p110δ Crystal Structure
por: Jia, Wenqing, et al.
Publicado: (2022)

Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry
por: Maccari, Maria Elena, et al.
Publicado: (2018)

PI3Kδ过度活化综合征一例
Publicado: (2021)

PI3Kδ inhibition causes feedback activation of PI3Kα in the ABC subtype of diffuse large B-cell lymphoma
por: Pongas, Georgios N., et al.
Publicado: (2017)

Immunological characterization of HM5023507, an orally active PI3Kδ/γ inhibitor
por: Cai, Yu, et al.
Publicado: (2020)

PI3K Signaling in Tissue Hyper-Proliferation: From Overgrowth Syndromes to Kidney Cysts
por: De Santis, Maria Chiara, et al.
Publicado: (2017)

Disorders Related to PI3Kδ Hyperactivation: Characterizing the Clinical and Immunological Features of Activated PI3-Kinase Delta Syndromes
por: Redenbaugh, Vyanka, et al.
Publicado: (2021)

PI3Kδ Is Essential for Tumor Clearance Mediated by Cytotoxic T Lymphocytes
por: Putz, Eva Maria, et al.
Publicado: (2012)

PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
por: Tarantelli, Chiara, et al.
Publicado: (2021)

Phosphatidylinositol 3-kinase-δ (PI3K-δ) is a potential therapeutic target in adult T-cell leukemia-lymphoma
por: Katsuya, Hiroo, et al.
Publicado: (2018)

Enhanced AKT Phosphorylation of Circulating B Cells in Patients With Activated PI3Kδ Syndrome
por: Asano, Takaki, et al.
Publicado: (2018)

Secondary C1q Deficiency in Activated PI3Kδ Syndrome Type 2
por: Hong, Ying, et al.
Publicado: (2019)

Is PI3K a Villain in Cystic Fibrosis?
por: Natarajan, Viswanathan
Publicado: (2020)

Characterization of selective and potent PI3Kδ inhibitor (PI3KD-IN-015) for B-Cell malignances
por: Liu, Xiaochuan, et al.
Publicado: (2016)

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors
por: Yahiaoui, Anella, et al.
Publicado: (2017)

TGFβ activates PI3K-AKT signaling via TRAF6
por: Song, Jie, et al.
Publicado: (2017)

Evaluation of Systems’ Irregularity and Complexity: Sample Entropy, Its Derivatives, and Their Applications across Scales and Disciplines
por: Humeau-Heurtier, Anne
Publicado: (2018)

Multiscale Entropy Approaches and Their Applications
por: Humeau-Heurtier, Anne
Publicado: (2020)

Occurrence of B-cell lymphomas in patients with Activated Phosphoinositide 3-Kinase δ syndrome
por: Kracker, Sven, et al.
Publicado: (2014)

Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3
por: Lauder, Sarah Nicol, et al.
Publicado: (2020)

Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approach
por: Lauder, Sarah N., et al.
Publicado: (2021)

Targeting PI3Kδ: One man’s meat is another man’s poison
por: Prchal-Murphy, Michaela, et al.
Publicado: (2013)

Anti-inflammatory potential of PI3Kδ and JAK inhibitors in asthma patients
por: Southworth, Thomas, et al.
Publicado: (2016)

PI3Kδ Inhibition as a Potential Therapeutic Target in COVID-19
por: Palma, Giuseppe, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qqftk2hvmhbf47frblli1h5rhm